A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults

← catalyst calendar

NCT07235163 · readout in 330 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

100estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-04-13

estimated

When the study began enrolling

Primary completion

2027-07-16

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-07-16

estimated

The whole study's end, after follow-up

First posted

2025-11-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy

Interventions

Drug: PF-08065010
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured Baseline, approximately up to 5 months

Number of Participants With Clinically Significant Laboratory Abnormalities

measured Baseline, approximately up to 5 months

Number of Participants With Vital Sign Abnormalities

measured Baseline, approximately up to 5 months

Number of Participants with Change from Baseline in Physical Exam (PE) Parameters

measured Baseline, approximately up to 5 months

Number of Participants with Change from Baseline in Electrocardiogram (ECG) Parameters

measured Baseline, approximately up to 5 months

Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)